Tech-enabled drug discovery company Insilico Medicine secured $110 million in an oversubscribed Series E funding round. A large equity fund of Value Partners Group, an asset management firm in Asia, and new and existing investors…
Continue Reading
Memorial Sloan Kettering Cancer Center is teaming up with AWS to accelerate its oncology research with AI, the health system announced Monday at the ViVE conference in Nashville.
By using AI to analyze vast amounts…
Continue Reading
The government has announced £82.6 million in research funding to support UK companies tackling cancer and accelerating drug discovery using AI.
Three projects will benefit from this support, two of which will use AI to…
Dr. Rakesh Nagarajan is the Chief Medical Officer at Velsera
The healthcare industry is experiencing a data and technological revolution that is accelerating drug discovery and delivery to patients. Over the past 15 years, we’ve…
Continue Reading
Top News
AI-powered cancer drug discovery startup Manas AI launches with a $25 million seed funding round.
The co-founders are LinkedIn co-founder and venture capitalist Reid Hoffman and oncologist-author Siddhartha Mukherjee, DPhil, MD, who wrote Pulitzer…
Accurately predicting binding affinities between drugs and targets is crucial for drug discovery but remains challenging due to the complexity of modeling interactions between small drug and large targets. This study proposes DMFF-DTA, a…
Continue Reading
Manas AI, an AI-driven drug discovery platform, has launched with $24.6 million in seed round in a round co-led by General Catalyst and LinkedIn cofounder Reid Hoffman. Greylock and other strategic investors participated in the…
Continue Reading
Absci, a data-first generative AI drug creation company, is partnering with AMD, a semiconductor company, to deploy AMD Instinct accelerators and ROCm software to power vital AI drug discovery workloads, as well as Absci’s…
Continue Reading
What You Should Know:
– TetraScience, a provider of scientific data cloud solutions announced a strategic collaboration with Microsoft to accelerate the adoption of artificial intelligence (AI) in the biopharmaceutical industry.
– The strategic partnership combines…
Continue Reading
Noam Solomon, CEO at Immunai
For over a decade, we’ve heard about AI’s transformative potential in therapeutics (Tx), but where’s the evidence? Has it all been hype? Can AI still revolutionize Tx? Or is there…
Continue Reading
